Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

Executive Summary

During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.

You may also be interested in...



Lilly/Incyte’s Olumiant Breezes Ahead of JAK Pack In Atopic Dermatitis

Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?

Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis

FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.

A Q&A With Lilly Biomedicines President Christi Shaw

The Eli Lilly & Co. executive talked with Scrip about the competitive dynamics facing Taltz, the status of baricitinib and launching galcanezumab in the crowded CGRP class, as well as about industry issues like drug rebates, drug pricing and gender diversity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC122958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel